Home   >  
Cell Cycle/DNA Damage

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products






Raw Materials


Chemical Structure Cat. No. Product Name CAS No.
LY3405105 Chemical Structure
BCP42676 LY3405105 2326428-25-3
LY3405105 is an orally active CDK7 inhibitor with an IC50 of 92.8 nM. LY3405105 shows potential antineoplastic activity.
MS140 Chemical Structure
BCP42677 MS140 2229974-83-6
MS140 is a specific and highly potent CDK4/6 kinase inhibitor and also a CDK4/6 degrader (PROTAC).
SB1317 Chemical Structure
BCP42651 SB1317 1204918-72-8
SB1317 is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. Zotiraciclib may be useful for the treatment of cancer that crosses the blood brain barrier and acts by depleting Myc through the inhibition of cyclin-dependent kinase 9 (CDK9). It is one of a number of CDK inhibitors under investigation; others targeting CDK9 for the treatment of acute myeloid leukemia include alvocidib and atuveciclib. Myc overexpression is a known factor in many cancers, with 80 percent of glioblastomas characterized by this property.
CDK4 inhibitor compound 12 Chemical Structure
BCP41586 CDK4 inhibitor compound 12 2105956-77-0
CDK4 inhibitor compound 12 is a novel inhibitor of CDK4 with the activity 97 μM.
KB-0742 Chemical Structure
BCP41310 KB-0742 2416873-83-9
KB-0742 is an orally bioavailable, selective CDK9 inhibitor with potent anti-tumor activity in CRPC models.
BSJ-4-116 Chemical Structure
BCP40986 BSJ-4-116 2519823-34-6
BSJ-4-116 selectively degraded CDK12 as assessed through quantitative proteomics.
YKL-5-124 Chemical Structure
BCP40930 YKL-5-124 1957203-01-8
YKL-5-124 is a potent and highly selective covalent CDK7 inhibitor which causes arrest at the G1/S transition and inhibition of E2F-driven gene expression.
GW805758X Chemical Structure
BCP38035 GW805758X GW805758X
GW805758X is a potent inhibitor of CDK-4 which demonstrates enzyme selectivity against VEGFR-2 and GSK3β.
FIT-039 Chemical Structure
BCP37988 FIT-039 1113044-49-7
FIT-039 is a potent, selective CDK9 inhibitor with IC50 of 5.8 uM for CKD9/cyclin T1, suppresses the replication of HSV-1 (IC50=0.69 uM).
CDKI-73 Chemical Structure
BCP37660 CDKI-73 1421693-22-2
CDKI-73 is a potent CDK9 inhibitor with Ki of 4 nM. It shows selective toxicity to CLL cells(LD50=80 nM) versus normal B cell and normal CD34+ cell(LD50>20 uM). The inhibition of CDK9 induces apoptosis and potentiates the effect of cisplatin.
123下一页末页共 125 条记录 1 / 13 页